• Derma Sciences Inc., of Princeton, N.J., said it met with the FDA to discuss Phase II results of investigational compound DSC127, a topical angiotensin analogue, in diabetic foot ulcers. The FDA supported the initiation of pivotal Phase III studies and offered guidance on trial design and other clinical activities, according to the company, which plans to initiate the Phase III trials in the second half of the year.
